Topical D-myo-inositol-1,2,6-trisphosphate and hexylbetaine treatment reduces albumin extravasation in experimental rat skin burn injury.
The anti-inflammatory agent D-myo-inositol-1,2,6-trisphosphate (1,2,6-IP3) has shown beneficial effects in experimental burns following systemic administration. The purpose of this study was to investigate the effect of topical 1,2,6-IP3 cream on a standardised full-thickness 1 cm2 burn injury in rats. The experimental cream contained a transcutaneous absorption enhancer, hexylbetaine. Five different treatment groups were used. Two experimental groups of burned rats received either 1,2,6-IP3 cream with hexylbetaine (n = 10) or without hexylbetaine (n = 10). Two burned control groups were treated either with hexylbetaine cream (n = 10) or placebo cream (n = 10), while a third control group was untreated (n = 14). The various creams (0.5 g) were administered to the experimental burn area and allowed to remain for 3 h covered with an occlusive dressing. Spectrophotometrical quantification of Evans blue albumin extravasation was used to evaluate the effect of the experimental creams on vascular permeability following the burn trauma. Results showed a significant reduction of albumin extravasation both by 1,2,6-IP3 (p<0.05) and by hexylbetaine alone (p<0.01), as compared to placebo cream-treated animals. The transcutaneous absorption enhancer hexylbetaine did not further improve the effect of 1,2,6-IP3 on burn oedema. In conclusion, both topical 1,2,6-IP3 and hexylbetaine induced a significant reduction of albumin extravasation in burned skin. The effect of 1,2,6-IP3 could be related to previously shown anti-inflammatory actions of the agent, while the mechanisms of actions of hexylbetaine remain to be investigated.
Tarnow
P
P
Department of Plastic Surgery, Sahlgrenska University Hospital, Göteborg, Sweden.
Jönsson
A
A
Lindblom
L
L
Gustafsson
T
T
Cassuto
J
J
D000287:Administration, Topical; D000418:Albumins / Q000032:analysis / Q000187:drug effects*; D000704:Analysis of Variance; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D001622:Betaine / Q000008:administration & dosage* / Q000031:analogs & derivatives; D002056:Burns / Q000188:drug therapy*; D016001:Confidence Intervals; D004195:Disease Models, Animal; D005070:Evans Blue / Q000032:analysis; D007295:Inositol Phosphates / Q000008:administration & dosage*; D008297:Male; D009779:Occlusive Dressings; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D012867:Skin / Q000737:chemistry / Q000187:drug effects* / Q000293:injuries; D013053:Spectrophotometry
D000418:Albumins; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007295:Inositol Phosphates; D001622:Betaine; D005070:Evans Blue; C059368:atrinositol